A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Lenvatinib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 07 Jun 2016 Results of final analysis presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 24 May 2016 According to an Eisai Co., media release, results from this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).
- 15 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.